The second affiliated hosipital zhejiang university school of medicine
Hangzhou, Zhejiang, 310000, China
NCT Number: NCT05862974
This is a randomized, double-blind, placebo-controlled, dose-increasing Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous infusion of LPM3480392 injection in healthy subject
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Hangzhou, Zhejiang, 310000, China
A total of 80 healthy subjects will be allocated to 1 of 8 cohorts (cohort 1~8) in the study, each cohort including 10 subjects (8 subjects will receive investigational new drug (IND) product and 2 receive placebo). Each subject in fasted state will be randomly assigned to receive a single dose of LPM3480392 or placebo intravenously.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous infusion of 30min duration
Intravenous infusion of 30min duration
Time frame: from baseline to day8
(including abnormal value of Vital signs,physical examination,laboratory tests,12-lead ECG)
Time frame: from baseline to day2
Drug effect questionnaire,
Time frame: from baseline to day3
Opiate Withdrawal Scale
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 48 hours after administration
Pharmacokinetic index
Time frame: baseline and 8 hours after administration
Pharmacodynamic index
Time frame: baseline and 8 hours after administration
Pharmacodynamic index
Luye Pharma Group Ltd.
Industry
A Randomized, Double-blind, Placebo-controlled, Dose-increasing Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Infusion of LPM3480392 Injection in Healthy Subject
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details